Hypotension	hypotension	O	S_disease
following	following	O	O
the	the	O	O
initiation	initiation	O	O
of	of	O	O
tizanidine	tizanidine	O	O
in	in	O	O
a	a	O	O
patient	patient	O	O
treated	treated	O	O
with	with	O	O
an	an	O	O
angiotensin	angiotensin	S_chemical	O
converting	converting	O	O
enzyme	enzyme	O	O
inhibitor	inhibitor	O	O
for	for	O	O
chronic	chronic	O	O
hypertension	hypertension	O	S_disease
.	.	O	O

Centrally	centrally	O	O
acting	acting	O	O
alpha-2	alpha-2	O	O
adrenergic	adrenergic	B_chemical	O
agonists	agonists	I_chemical	O
are	are	O	O
one	one	O	O
of	of	O	O
several	several	O	O
pharmacologic	pharmacologic	O	O
agents	agents	O	O
used	used	O	O
in	in	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
spasticity	spasticity	O	O
related	related	O	O
to	to	O	O
disorders	disorders	O	O
of	of	O	O
the	the	O	O
central	central	O	O
nervous	nervous	O	O
system	system	O	O
.	.	O	O

In	in	O	O
addition	addition	O	O
to	to	O	O
their	their	O	O
effects	effects	O	O
on	on	O	O
spasticity	spasticity	O	O
,	,	O	O
certain	certain	O	O
adverse	adverse	O	O
cardiorespiratory	cardiorespiratory	O	O
effects	effects	O	O
have	have	O	O
been	been	O	O
reported	reported	O	O
.	.	O	O

Adults	adults	O	O
chronically	chronically	O	O
treated	treated	O	O
with	with	O	O
angiotensin	angiotensin	S_chemical	O
converting	converting	O	O
enzyme	enzyme	B_chemical	O
inhibitors	inhibitors	I_chemical	O
may	may	O	O
have	have	O	O
a	a	O	O
limited	limited	O	O
ability	ability	O	O
to	to	O	O
respond	respond	O	O
to	to	O	O
hypotension	hypotension	O	S_disease
when	when	O	O
the	the	O	O
sympathetic	sympathetic	O	O
response	response	O	O
is	is	O	O
simultaneously	simultaneously	O	O
blocked	blocked	O	O
.	.	O	O

The	the	O	O
authors	authors	O	O
present	present	O	O
a	a	O	O
10-year-old	10-year-old	O	O
boy	boy	O	O
chronically	chronically	O	O
treated	treated	O	O
with	with	O	O
lisinopril	lisinopril	O	O
,	,	O	O
an	an	O	O
angiotensin	angiotensin	S_chemical	O
converting	converting	O	O
enzyme	enzyme	O	O
inhibitor	inhibitor	O	O
,	,	O	O
to	to	O	O
control	control	O	O
hypertension	hypertension	O	S_disease
who	who	O	O
developed	developed	O	O
hypotension	hypotension	O	S_disease
following	following	O	O
the	the	O	O
addition	addition	O	O
of	of	O	O
tizanidine	tizanidine	O	O
,	,	O	O
an	an	O	O
alpha-2	alpha-2	O	O
agonist	agonist	O	O
,	,	O	O
for	for	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
spasticity	spasticity	O	O
.	.	O	O

The	the	O	O
possible	possible	O	O
interaction	interaction	O	O
of	of	O	O
tizanidine	tizanidine	O	O
and	and	O	O
other	other	O	O
antihypertensive	antihypertensive	B_chemical	O
agents	agents	I_chemical	O
should	should	O	O
be	be	O	O
kept	kept	O	O
in	in	O	O
mind	mind	O	O
when	when	O	O
prescribing	prescribing	O	O
therapy	therapy	O	O
to	to	O	O
treat	treat	O	O
either	either	O	O
hypertension	hypertension	O	S_disease
or	or	O	O
spasticity	spasticity	O	O
in	in	O	O
such	such	O	O
patients	patients	O	O
.	.	O	O

